Jascayd

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Idiopathic Pulmonary FibrosisInterstitial Lung DiseaseRheumatic DiseasePulmonary Fibrosis

179 competitors in Idiopathic Pulmonary Fibrosis

#DrugCompanyPhaseTrials

1

Thalomid

Bristol-Myers Squibb

Phase 3

22

Tracleer

Johnson & Johnson

Phase 3

23

Prevacid

Takeda

Phase 3

14

Letairis

Gilead

Phase 3

15

Gleevec

Novartis

Phase 3

16

MS Contin

Merck & Co.

Phase 3

—7

Jascayd

Boehringer Ingelheim

Phase 3

18

Cytoxan

BBaxter Healthcare Corporation

Phase 3

19

Coumadin

AAbbott

Phase 3

110

Minocin

TTriax

Phase 3

1Show 31 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

MPA2 trials

A Study in Healthy People to Compare How 2 Different High Dose Formulations of BI 1015550 Are Taken up in the Body

Completed·Boehringer Ingelheim·Phase 1·NCT06393127·64 enrolled

A Study in Healthy People to Compare 2 Different Formulations of Nerandomilast Tablets When Taken With or Without Food

Completed·Boehringer Ingelheim·Phase 1·NCT06624072·15 enrolled

Interstitial Lung Diseases2 trials

A Double Blind, Randomised, Placebo-controlled Trial Evaluating the Efficacy and Safety of Nerandomilast Over at Least 26 Weeks in Patients With Systemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases (SARD-ILD)

Recruiting·Boehringer Ingelheim·Phase 3·NCT06806592·400 enrolled

A Double-blind, Randomized, Placebo-controlled Trial Investigating the Efficacy and Safety of Nerandomilast Over at Least 52 Weeks in Patients With Fibrosing Interstitial Lung Disease at Risk for Disease Progression (FIBRONEER-ACT)

Not yet recruiting·Boehringer Ingelheim·Phase 3·NCT07540988·466 enrolled

BOS1 trial

A Study in Healthy Men to Test How Bosentan Influences the Amount of Nerandomilast in the Blood

Completed·Boehringer Ingelheim·Phase 1·NCT07081932·16 enrolled

CAR1 trial

A Study in Healthy Men to Test Whether Carbamazepine Influences the Amount of Nerandomilast in the Blood

Completed·Boehringer Ingelheim·Phase 1·NCT07100964·16 enrolled

Idiopathic Pulmonary Fibrosis1 trial

An Open-label Extension Trial of the Long-term Safety and Efficacy of BI 1015550 Taken Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF) and Progressive Pulmonary Fibrosis (PPF) (FIBRONEER™-ON)

Recruiting·Boehringer Ingelheim·Phase 3·NCT06238622·1,700 enrolled

3 more indications

Pulmonary Fibrosis1 trial

A Double Blind, Randomized, Placebo-controlled Exploratory Trial to Investigate the Efficacy and Safety of Nerandomilast Over 24 Months When Administered in Individuals With Interstitial Lung Abnormalities and a Family History of Pulmonary Fibrosis to Reduce the Risk of Worsening (DROP-FPF)

Recruiting·Boehringer Ingelheim·Phase 3·NCT07201922·80 enrolled

Interstitial Lung Disease1 trial

A Study to Evaluate the Dose-exposure, Safety, and Exploratory Efficacy of Nerandomilast in Children and Adolescents From 2 Years to Less Than 18 Years of Age With Fibrosing Interstitial Lung Disease (Part A: Double-blind, Placebo-controlled in Children From 6 to Less Than 18 Years of Age and Open-label Active Treatment in Children From 2 to Less Than 6 Years of Age), Followed by an Open-label Phase With Active Treatment (Part B)

Not yet recruiting·Boehringer Ingelheim·Phase 3·NCT07366034·35 enrolled

Unspecified1 trial

A Study to Test How Different Doses of Nerandomilast (BI 1015550) Are Taken up in the Body of Healthy Japanese Men

Completed·Boehringer Ingelheim·Phase 1·NCT06139302·12 enrolled

Regulatory

FDA Approval Timeline[4]

Details

Drug Info

Patent Landscape[5]

Related News